Floatz logo

Wztl002-1

Follicular Lymphoma (FL)

Malaghan Institute of Medical ResearchCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Follicular Lymphoma (FL) cohort.

Asset / SponsorPhaseRating
Odronextamab
Gottfried von Keudell, MD PhD
Phase 3B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Sun Yat-sen University
Phase 3B
tc011
TICAROS Co., Ltd.
Phase 2B
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Regeneron Pharmaceuticals
Phase 3B
Sctb35
Sinocelltech Ltd.
Phase 3B

View all 22 →

Same molecule, other indications

Wztl002-1 is also rated in:

follicular lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →